Immunocore announces R&D chief resignation and leadership reshuffle

The latest announcement is out from Immunocore Holdings ( (IMCR) ).

On January 27, 2026, Immunocore Holdings plc announced that its Head of Research & Development, David Berman, had submitted his resignation, effective February 27, 2026, to pursue another opportunity, with the company noting that his departure did not stem from any disagreement related to its operations, policies or practices. Immunocore stated it will not recruit a direct replacement for Berman and instead plans to streamline and rely on its existing R&D structure, signaling an internal reorganization of its research leadership that could affect how the company manages and advances its development pipeline.

The most recent analyst rating on (IMCR) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Immunocore Holdings stock, see the IMCR Stock Forecast page.

Spark’s Take on IMCR Stock

According to Spark, TipRanks’ AI Analyst, IMCR is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses and sharply deteriorating free cash flow) and bearish technicals (negative MACD and trading below major moving averages). A positive offset comes from supportive corporate developments, including a well-funded clinical and commercial roadmap (about $864M cash) and plans for multiple 2026 trial readouts, but valuation remains unattractive due to unprofitable earnings (negative P/E).

To see Spark’s full report on IMCR stock, click here.

More about Immunocore Holdings

Immunocore Holdings plc is a biotechnology company focused on research and development activities, with operations centered on advancing its scientific and therapeutic programs within the biopharmaceutical industry.

Average Trading Volume: 364,039

Technical Sentiment Signal: Sell

Current Market Cap: $1.67B

For a thorough assessment of IMCR stock, go to TipRanks’ Stock Analysis page.